EP4719375A1 — Solriamfetol for treating cognitive impairment in a subject with impaired cognition associated with obstructive sleep apnea and excessive daytime sleepiness
Assigned to Axsome Therapeutics Inc · Expires 2026-04-08 · 0y expired
What this patent protects
The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to enhance one or more cognitive function in a subject with impaired cognition associated with obstructive sleep apnea and excessive daytime sleepiness and to treat one or more cogni…
USPTO Abstract
The present invention relates to carbamoyl phenylalaninol compounds and methods of using the same to enhance one or more cognitive function in a subject with impaired cognition associated with obstructive sleep apnea and excessive daytime sleepiness and to treat one or more cognitive impairment in such a patient.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.